Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1999 2
2002 1
2003 1
2004 1
2005 1
2008 2
2009 5
2010 5
2011 5
2012 10
2013 12
2014 8
2015 11
2016 10
2017 7
2018 12
2019 14
2020 18
2021 10
2022 10
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.
van der Ploeg P, Hendrikse CS, Thijs AM, Westgeest HM, Smedts HP, Vos MC, Jalving M, Lok CA, Boere IA, van Ham MA, Ottevanger PB, Westermann AM, Mom CH, Lalisang RI, Lambrechts S, Bekkers RL, Piek JM. van der Ploeg P, et al. Among authors: ottevanger pb. Heliyon. 2023 Dec 1;10(1):e23170. doi: 10.1016/j.heliyon.2023.e23170. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187310 Free PMC article.
Potential Adverse Outcomes of Shared Decision Making about Palliative Cancer Treatment: A Secondary Analysis of a Randomized Trial.
van de Water LF, Bos-van den Hoek DW, Kuijper SC, van Laarhoven HWM, Creemers GJ, Dohmen SE, Fiebrich HB, Ottevanger PB, Sommeijer DW, de Vos FYF, Smets EMA, Henselmans I. van de Water LF, et al. Among authors: ottevanger pb. Med Decis Making. 2024 Jan;44(1):89-101. doi: 10.1177/0272989X231208448. Epub 2023 Nov 12. Med Decis Making. 2024. PMID: 37953598 Free PMC article. Clinical Trial.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Ledermann JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Kobie J, Nebozhyn M, Edmondson M, Sun Y, Cristescu R, Jelinic P, Keefe SM, Matulonis UA. Ledermann JA, et al. Among authors: ottevanger pb. Gynecol Oncol. 2023 Nov;178:119-129. doi: 10.1016/j.ygyno.2023.09.012. Epub 2023 Oct 18. Gynecol Oncol. 2023. PMID: 37862791
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Ottevanger PB, Bloemendal HJ, Koolen SLW, Mathijssen RHJ, Boere IA, Hamberg P, Huitema ADR, Sonke GS, Opdam FL, Ter Heine R, van Erp NP. Overbeek JK, et al. Among authors: ottevanger pb. Eur J Cancer. 2023 Nov;194:113346. doi: 10.1016/j.ejca.2023.113346. Epub 2023 Sep 19. Eur J Cancer. 2023. PMID: 37806255 Free article. Clinical Trial.
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE, Theelen PMM, van der Ploeg P, Westgeest HM, Boere IA, Thijs AMJ, Ottevanger PB, van de Stolpe A, Lambrechts S, Bekkers RLM, Piek JMJ. Hendrikse CSE, et al. Among authors: ottevanger pb. Gynecol Oncol. 2023 Apr;171:83-94. doi: 10.1016/j.ygyno.2023.01.038. Epub 2023 Feb 24. Gynecol Oncol. 2023. PMID: 36841040 Free article. Review.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
Attitudes Toward Striving for Quality and Length of Life Among Patients With Advanced Cancer and a Poor Prognosis.
van der Velden NCA, van Laarhoven HWM, Nieuwkerk PT, Kuijper SC, Sommeijer DW, Ottevanger PB, Fiebrich HB, Dohmen SE, Creemers GJ, de Vos FYFL, Smets EMA, Henselmans I. van der Velden NCA, et al. Among authors: ottevanger pb. JCO Oncol Pract. 2022 Nov;18(11):e1818-e1830. doi: 10.1200/OP.22.00185. Epub 2022 Oct 6. JCO Oncol Pract. 2022. PMID: 36201709 Clinical Trial.
130 results